Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) EBITDA: 2017-2019

Historic EBITDA for Monopar Therapeutics (MNPR) over the last 3 years, with Dec 2019 value amounting to -$1.2 million.

  • Monopar Therapeutics' EBITDA fell 35.39% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.2 million, marking a year-over-year decrease of 38.86%. This contributed to the annual value of -$4.2 million for FY2019, which is 31.05% down from last year.
  • As of Q4 2019, Monopar Therapeutics' EBITDA stood at -$1.2 million, which was down 61.87% from -$744,819 recorded in Q3 2019.
  • In the past 5 years, Monopar Therapeutics' EBITDA registered a high of -$372,917 during Q2 2017, and its lowest value of -$14.9 million during Q3 2017.
  • Its 3-year average for EBITDA is -$2.0 million, with a median of -$810,583 in 2018.
  • Data for Monopar Therapeutics' EBITDA shows a peak YoY increase of 95.69% (in 2018) and a maximum YoY decrease of 134.42% (in 2018) over the last 5 years.
  • Over the past 3 years, Monopar Therapeutics' EBITDA (Quarterly) stood at -$713,583 in 2017, then declined by 24.79% to -$890,472 in 2018, then tumbled by 35.39% to -$1.2 million in 2019.
  • Its EBITDA was -$1.2 million in Q4 2019, compared to -$744,819 in Q3 2019 and -$904,633 in Q2 2019.